[Skip to Content]
[Skip to Content Landing]
Comment & Response
July 24/31, 2013

Sildenafil and Exercise Capacity in Heart Failure—In Reply

Author Affiliations
  • 1Heart Failure Clinical Research Network, Mayo Clinic, Rochester, Minnesota
JAMA. 2013;310(4):432-433. doi:10.1001/jama.2013.7440

In Reply Dr Guazzi and colleagues suggest that the presence of comorbidities such as obesity, atrial dysrhythmias, and anemia might have made patients with HFPEF less apt to derive benefit from phosphodiesterase-5 inhibition. These comorbidities are typical in patients with HFPEF in the community.1 Heart failure with normal EF in the absence of comorbidities is usually termed restrictive cardiomyopathy, and this is a much less common form of HF than the type that we set out to study in the RELAX trial.